A personalized cancer vaccine has shown positive results in late-stage trials for melanoma treatment. Drugmakers Moderna and Merck announced the advance, involving a combination of an existing cancer immunotherapy drug and a custom-made mRNA therapy.

The treatment is designed specifically for each patient's tumor, using unique mutations identified after surgery. The companies plan to share full results at upcoming medical meetings and with regulators, but have not disclosed the data yet.

Further details on the trial and treatment are expected to be released by the companies. The personalized cancer vaccine offers a new approach to treating melanoma, a dangerous form of skin cancer.